🔴 BioLineRx is trading 6.79% down in pre-market after second-quarter revenue missed estimates

BioLineRx is trading 6.79% down in pre-market at $2.61 after second-quarter revenue of $0.3 million missed the $0.5 million analyst estimate.

• In its August 31, 2026, report, APHEXDA sales generated $0.3 million in royalty revenue.
• The company reported a $4.3 million net loss and completed a $3.75 million offering, creating potential dilution.
• Management highlighted GLIX1 clinical expansion and cash runway into the first half of 2027.